IPO News | Jia Yin Biotechnology Files Again for Hong Kong Stock Exchange

15:40 29/08/2026

According to the Hong Kong Stock Exchange's disclosure on August 28, Exegenesis Bio Inc. (referred to as: ) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC acting as its sole sponsor.

According to the Hong Kong Stock Exchange's disclosure on August 28, Exegenesis Bio Inc. (referred to as: ) has submitted a listing application to the main board of the Stock Exchange, with CCB International as its exclusive sponsor. The prospectus reveals that is a biopharmaceutical company focused on the discovery and development of gene therapies for neurological and ophthalmic diseases. The company's pipeline also includes oligonucleotide therapies. Established in 2019, the company has built a pipeline of nine candidate products through its fully integrated in-house R&D platform. Through this platform, the company has internally developed two core products (EXG102-031 and EXG001-307 (SMA Type 1)) and one key product (EXG202).

Commentary on the China International Capital Corporation (CICC) Jackson Hole Meeting: The Late-arriving Hawk and the Repair of Credibility

New Stock News | Nuoling Biotechnology has submitted its application to the Hong Kong Stock Exchange again, with its products now covering 31 provinces nationwide.

New Stock News | Zhejiang Chint Electrics (601877.SH) has submitted its application to the Hong Kong Stock Exchange, maintaining its position as the leading brand in China's low voltage electrical product exports for three consecutive years.

Commentary on the China International Capital Corporation (CICC) Jackson Hole Meeting: The Late-arriving Hawk and the Repair of Credibility

New Stock News | Nuoling Biotechnology has submitted its application to the Hong Kong Stock Exchange again, with its products now covering 31 provinces nationwide.